TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04809207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CF Wellness Program Sessions
Description: The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.
Study: NCT05647265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: undergo CT
Study: NCT04829799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% preservative-free lidocaine
Description: Instillation of intracameral lidocaine after initial paracentesis incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine 1.0%/ Ketorolac 0.3%
Description: Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
Study: NCT01045941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Gemzar
Description: Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Distal pancreatectomy
Description: Laparoscopic resection of the distal pancreas
Study: NCT04997993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Leflunomide, 20-50mg PO daily
Study: NCT06034236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Task oriented resistance training will be performed, there will be 10 workstations:~1. Sitting at a table and reaching in different directions for objects located beyond arm's length.~2. Sit to stand from various chair heights~3. Stepping forward, backward and sideways onto blocks of various heights.~4. Heel lifts in standing~5. Standing with narrow base of support, feet in parallel and tandem stance and reaching for objects, including down to the floor.~6. Reciprocal leg flexion and extension.~7. Sit ups~8. Standing up from chair, walking a short distance and returning to the chair.~9. Walking races between participants~10. Walking over various surfaces and obstacles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercises
Description: It has total 17 exercises, out of which 12 exercises are performed to improve balance and 5 are performed to improve strength.~1. First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~2. Second component is muscle strengthening exercises, it includes: i. Front knee strengthening exercise ii. Back knee strengthening exercise iii. Side hip strengthening exercise iv. Calf raises (with support and without support) v. Toe raise (with support and without support). 3. Third component is balance exercises, it includes: i. Knee bends ii. Backward walking iii. Heel toe standing iv. Heel toe walking v. One leg stand vi. Heel walking vii. Sideways walk viii. Toe walking ix. Heel toe walking backwards x. Walk and turn around (figure of 8) xi. Sit to stand xii. Stair walks
Study: NCT04566991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine.
Study: NCT06211595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragonFire Transcatheter Myocardial Radiofrequency Ablation System
Description: The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
Study: NCT04566991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
Study: NCT06028659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: 150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
Study: NCT06074315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nail Genesis DLSO Product
Description: Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nail Genesis DLSO Product (vehicle only)
Description: The Nail Genesis DLSO product poly-urethane vehicle
Study: NCT05950009

Intervention type: OTHER
Intervention: No intervention (observational studies)
Description: No intervention (observational studies)

Intervention type: OTHER
Intervention: No intervention (observational studies)
Description: No intervention (observational studies)
Study: NCT04756791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAPB
Description: local anesthetic is injected between the serratus anterior and latissimus dorsi muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Injection Anesthesia
Description: Anesthesia is injected directly into the tissue that is will be numbing.
Study: NCT05427253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C106 solution
Description: selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for C106 solution
Study: NCT06507592

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saliva samples collection
Description: The first sample of saliva was be taken before the start of the treatment and considered as the control sample (T0); the second sample was be taken one month after the start of the treatment (T1) and the third one after three months (T2).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saliva samples collection
Description: The first sample of saliva was be taken before the start of the treatment and considered as the control sample (T0); the second sample was be taken one month after the start of the treatment (T1) and the third one after three months (T2).
Study: NCT05729659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sideritis Scardica (SidTea+) extract supplementation
Description: 1500 mg of Sideritis Scardica (SidTea+) extract per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: 1500 mg of placebo per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
Study: NCT06087276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg ulixacaltamide
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg ulixacaltamide
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg ulixacaltamide
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg ulixacaltamide
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral treatment
Study: NCT05430737

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: The radiation dose to the primary tumor was 40 or 45 Gy in five fractions according to the clinical determination of the radiologist. The dose to the positive lymph nodes and the prostate and seminal vesicles was 37.5Gy in five fraction. And internal iliac, external iliac, obturator, and presacral pelvic drainage regions received 25 Gy/5f, simultaneously. The treatment was delivered every other day. The volumetric modulated arc radiotherapy (VMAT) or intensity-modulated radiotherapy (IMRT) was used to complete treatment. Image-guided radiotherapy(IGRT) was performed for every treatment.
Study: NCT06474585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plantar orthosis
Description: Plantar orthosis taken in sitting position Plantar orthosis taken in standing position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plantar orthosis
Description: Plantar orthosis taken in sitting position Plantar orthosis taken in standing position
Study: NCT05647265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT06231615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascia exercises
Description: Fascia exercises are slow and calm movements similar to yoga performed by the person herself/himself.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physiotherapy and breathing exercises
Description: Head and neck exercises and breathing exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy and breathing exercises
Description: Head and neck exercises and breathing exercises
Study: NCT05585697

Intervention type: OTHER
Intervention: None - crossectional
Description: None - crossectional
Study: NCT06434844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupunctures
Description: After disinfection of the external ear with 75% alcohol wipes, 018x 13 filiform needles (Mocm International Limited) will be used to perform the auricular acupunctures at the relaxation point, tranquilizer point and master cerebral point at the left and right external ears.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Auricular acupunctures
Description: After disinfection of the external ear with 75% alcohol wipes, 018x 13 filiform needles (Mocm International Limited) will be used to perform the auricular acupunctures at the relaxation point, tranquilizer point and master cerebral point at the left and right external ears.
Study: NCT06086054

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigation and EMR referral to childcare facility
Description: See arm description
Study: NCT06434844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham acupunctures
Description: The auricular acupoints of finger, shoulder and tonsil will be targeted instead. These points are also located at the external ear and comparable to those in the intervention group. The external ear will be disinfected with 75% alcohol wipes. Auricular acupunctures with 018x 13 filiform needles (Mocm International Limited) will be carried out at the finger point, shoulder point and tonsil point of the left and right external ears.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupunctures
Description: The auricular acupoints of finger, shoulder and tonsil will be targeted instead. These points are also located at the external ear and comparable to those in the intervention group. The external ear will be disinfected with 75% alcohol wipes. Auricular acupunctures with 018x 13 filiform needles (Mocm International Limited) will be carried out at the finger point, shoulder point and tonsil point of the left and right external ears.
Study: NCT04825418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artic Sun
Description: 1. Induction phase A. Temperature using by esophageal or bladder thermometer. B. Application of a surface cooling device (Arctic Sun) C. Target temperature: 35 ± 0.5 °C D. Induction should be initiated as soon as possible after surgery (less than 6 hours)~2. Maintain phase A. Maintain duration : at least 72 hours and duration can be prolonged according to patient's clinical status B. Use the bedside shivering assessment scale (BSAS) and anti-shivering protocol C. Neuromuscular blocker can be used according to the discretion of the attending physician D. Lung-protective ventilation strategies including low-tidal volume are recommended E. Prophylactic antibiotics can be used to prevent pneumonia during hypothermia~3. Rewarming phase A. Rewarming rate: 0.05 - 0.1 ℃/hr (about 20 - 40 hours) to 37 ℃
Study: NCT05410847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Nab-Paclitaxel S-1
Description: Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
Study: NCT04381637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPE monitor
Description: NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tetanic stimulations
Description: Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3.
Study: NCT06464900

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: Provide patients with regular medication guidance, dietary guidance, exercise guidance and knowledge about diabetes mellitus and hypoglycaemia; test and record blood glucose regularly every day; answer patients' clinical questions and provide psychological support in a timely manner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Based on BCW Theory of Health Education
Description: BCW theory was applied to analyse behaviour and develop interventions in terms of capability, motivation and opportunity. Capability: Intensive daily management of diabetes through intervention functions (education, training, persuasion, modelling) to change attitudes and habits, understand the negative consequences of fear of hypoglycaemia, improve hypoglycaemia awareness and self-regulation skills. Opportunity: Through the intervention function (education, training, realization) to improve the awareness of hypoglycemia awareness, timely detection of hypoglycemia. In the event of a hypoglycaemic event patients know how to deal with it. Motivation: Through intervention functions (environmental reconstruction, realisation) that take full account of external factors and their own opportunities. Glucose management through microsoft platforms, on-site teaching and coaching by specialist nurses to create opportunities for patients who can change excessive/avoidant behaviours.
Study: NCT05851872

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiogram
Description: Being done per standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiogram
Description: Being done per standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right heart catheterization
Description: Being done per standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right heart catheterization
Description: Being done per standard of care
Study: NCT04453085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-171 (lepunafusp alfa)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-171 (lepunafusp alfa)
Description: IV infusion
Study: NCT05061745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Meditation VR for Wellness
Description: Selected Modules of Commercially Available Guided Meditation VR presented on Valve Index Headset

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Transcranial Magnetic Stimulation: Treatment A
Description: Either MagVenture Transcranial Magnetic Stimulation (Treatment Coil Cool B70 AP) or The NeuroStar® System will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Transcranial Magnetic Stimulation: Treatment B
Description: Either MagVenture Transcranial Magnetic Stimulation (Cool D-B80 AP) or The NeuroStar® System will be used.
Study: NCT05625672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Hemovigilance module training
Study: NCT05819515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunneled coronally advanced flap
Description: Describes the flap design for both treatment arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneled coronally advanced flap
Description: Describes the flap design for both treatment arms
Study: NCT05062681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive dexamethasone 8 mg q12hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
Study: NCT06391723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS will be administered over the left dorsolateral prefrontal cortex
Study: NCT05807100

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline Standardized Mini Mental Test
Description: Cognitive status assessment was done with Standardized Mini Mental Test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline Standardized Mini Mental Test
Description: Cognitive status assessment was done with Standardized Mini Mental Test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline Standardized Mini Mental Test
Description: Cognitive status assessment was done with Standardized Mini Mental Test.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6th month Standardized Mini Mental Test
Description: Cognitive status assessment was done with Standardized Mini Mental Test.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6th month Standardized Mini Mental Test
Description: Cognitive status assessment was done with Standardized Mini Mental Test.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6th month Standardized Mini Mental Test
Description: Cognitive status assessment was done with Standardized Mini Mental Test.
Study: NCT05235958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-linear periodized exercise (NLPE)
Description: Aerobic training derived from professional sports, that is characterized by variable periodization of training frequency, volume and intensity according to individual factors, such as physical and mental readiness, training progress and performance level

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise counselling
Description: Standard recommendations for exercise and physical activity, that are individualized according to a medical health and fitness profile
Study: NCT06219837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine injection by ultrasound guided transversalis fascia plane block
Description: With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine injection by ultrasound guided transversalis fascia plane block
Description: With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.
Study: NCT05788588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR19006
Description: An emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume, administered via a central venous line over a time period of approximately 15 hours per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: All-in-one parenteral nutrition
Description: Trial participants are prescribed TPN by the attending physician, which will be administered via a central venous line over a time period of approximately 15 hours per day. The formulation is an emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume (nitrogen content, heat and liquid quantity as equal as HR19006).